CDKN2AIPNL Activators
CDKN2AIPNL activators encompass a range of compounds that enhance its activity through various cellular mechanisms and signaling pathways. Compounds that increase intracellular cyclic AMP levels either by direct activation of adenylate cyclase or through beta-adrenergic receptor stimulation lead to the activation of protein kinase A. The activated kinase can phosphorylate CDKN2AIPNL, thereby enhancing its activity. Similarly, cAMP analogs that are resistant to degradation by cellular phosphodiesterases ensure prolonged protein kinase A activation, which sustains the phosphorylation status of CDKN2AIPNL, contributing to its continuous activation. Additionally, inhibition of phosphodiesterases results in the accumulation of cAMP, which further sustains the activation state of protein kinase A and, by extension, CDKN2AIPNL.
On another front, compounds that modulate intracellular calcium levels can activate calmodulin-dependent kinases, which may phosphorylate CDKN2AIPNL if it falls under the purview of calcium/calmodulin-dependent regulation. Activation of AMP-activated protein kinase by certain agents could also initiate a phosphorylation cascade that potentially includes CDKN2AIPNL as a substrate. Furthermore, specific receptor agonists can alter gene expression patterns, leading up to the activation of CDKN2AIPNL by upregulating interacting proteins or pathways that modulate its function. Additionally, histone deacetylase inhibitors may affect the chromatin structure surrounding the CDKN2AIPNL gene, potentially enhancing its transcription and subsequent protein expression. This epigenetic modulation can result in increased levels of CDKN2AIPNL, which, when combined with post-translational modifications such as phosphorylation, could significantly enhance its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels. Elevated cAMP enhances the activity of protein kinase A (PKA), which can phosphorylate and thereby activate CDKN2AIPNL, as CDKN2AIPNL is regulated by phosphorylation events. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
This cAMP analog is resistant to degradation by phosphodiesterases and mimics the action of cAMP by activating PKA. The activation of PKA can subsequently lead to phosphorylation and activation of CDKN2AIPNL. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 5 g 100 g 250 g 1 kg 5 kg | $32.00 $66.00 $95.00 $188.00 $760.00 | 13 | |
As a phosphodiesterase inhibitor, caffeine prevents the breakdown of cAMP, resulting in sustained PKA activation. This can promote the phosphorylation and subsequent activation of CDKN2AIPNL. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calmodulin-dependent kinase (CaMK). CaMK could then activate CDKN2AIPNL if it is subject to regulation by calcium/calmodulin-dependent phosphorylation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
This beta-adrenergic agonist increases cAMP levels by stimulating adenylate cyclase, leading to PKA activation. PKA can then phosphorylate and activate CDKN2AIPNL. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR activates AMP-activated protein kinase (AMPK), which may lead to the phosphorylation and activation of CDKN2AIPNL if it is a substrate or is regulated by AMPK-related pathways. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
As a PPAR-gamma agonist, pioglitazone can promote the transcription of genes involved in the regulation of cell cycle and apoptosis, possibly leading to the upregulation of pathways that activate CDKN2AIPNL. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid modulates gene expression through retinoic acid receptors. This modulation may upregulate proteins that interact with or modify CDKN2AIPNL, leading to its activation. | ||||||
Bisphenol A | 80-05-7 | sc-391751 sc-391751A | 100 mg 10 g | $300.00 $490.00 | 5 | |
Bisphenol A is known to interact with estrogen receptors, which can influence gene expression and cellular pathways related to cell cycle control where CDKN2AIPNL may play a role, resulting in its activation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
This cAMP analog activates PKA, leading to the phosphorylation of downstream proteins. If CDKN2AIPNL is regulated by PKA-dependent phosphorylation, this compound would result in its activation. | ||||||